PMGC Holdings’ Northstrive Amends Development And License Agreement With Yuva Biosciences To Launch Three-Phase Program Advancing Four AI-Discovered Compounds And Updating AI Scope, IP, Field Of Use, And Financial Terms
Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup.The